NCT03695952View on ClinicalTrials.gov

A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors

Active, not recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

July 30, 2025

Study Completion Date

July 30, 2026

Conditions
Hepatocellular CarcinomaBiliary Tract Cancer
Interventions
DRUG

Nivolumab or pembrolizumab

Nivolumab 3 mg/kg intravenous every 2 weeks; Pembrolizumab 200 mg intravenous every 3 weeks

Trial Locations (1)

05505

Changhoon Yoo, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER